The field of laser cataract surgery continues to evolve with the Dec. 22 announcement by OptiMedica that its proprietary laser system received FDA 510(k) market clearance for capsulotomy and lens fragmentation.
A new method of drug delivery for ocular hypertensive therapies cannot be expected to be generally available for 4 or more years from now.
Genetic research has identified genes that can cause glaucoma primarily on their own and genes that require involvement of multiple genes and environmental factors in order for the disease to develop.
The use of cryopreserved amniotic membrane tissue on the ocular surface can modulate inflammation and promote healing without scarring in adults.
The advent of femtosecond laser technology for cataract surgery has resulted in myriad issues for ophthalmologists to face: the actual benefits of the laser versus the cost to patients, establishment of the patient share of the costs, associated financial risks for the practice and ambulatory surgery center, advertising, and patient satisfaction.
Uveitic glaucoma in children is a common complication of anterior uveitis that often coexists with cataract and band keratopathy.
Genotyping of patients to determine the risk of progression to advanced age-related macular degeneration is going to be a critical part of current/ongoing clinical trials and those in the future.
For the retina subspecialty, the past year was one of controversy, technologic advances, and an important approval from the FDA, as well as a surprise decision from the agency.
This year was one in which the femtosecond laser and its applications in refractive and cataract surgery and variations in the applications of crosslinking really began to blossom.
The FDA has approved aflibercept for the treatment of neovascular age-related macular degeneration.